GW Pharmaceuticals Plc
(Other OTC/NBB : GWPRF)

( )
GWPRF PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
2.06%21.3314.1%$125.51m
MDCOMedicines Company
1.72%53.0920.3%$104.73m
GWPHGW Pharmaceuticals PLC Sponsored ADR
3.55%120.336.2%$95.99m
AMRNAmarin Corporation Plc Sponsored ADR
2.65%15.861.8%$84.76m
JAZZJazz Pharmaceuticals Plc
0.34%118.052.3%$59.26m
SAGESAGE Therapeutics, Inc.
3.54%144.268.6%$55.96m
PRGOPerrigo Co. Plc
1.45%53.826.8%$52.09m
PCRXPacira Pharmaceuticals, Inc.
4.07%38.1010.5%$45.60m
UTHRUnited Therapeutics Corporation
0.89%81.9714.3%$39.43m
CTLTCatalent Inc
1.84%49.232.4%$35.25m
HZNPHorizon Pharma plc
3.35%28.206.6%$35.07m
ICLRICON Plc
0.27%141.024.1%$32.80m
ICPTIntercept Pharmaceuticals, Inc.
5.62%64.2516.9%$32.03m
AERIAerie Pharmaceuticals, Inc.
2.92%20.286.8%$28.14m
AXSMAxsome Therapeutics, Inc.
13.10%20.632.0%$25.52m

Company Profile

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its lead cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.